Let’s talk

API manufacturers · Pharmaceutical and life sciences

Batch cost for API manufacturers, built from the yield each campaign actually achieved

An API manufacturer prices a molecule on the yield it expects and earns on the yield it gets. We cost each campaign from actual yield, solvent recovery and changeover time. The price offered to the next buyer then rests on the plant's own record.

In one paragraph

Active pharmaceutical ingredient and intermediate manufacturers run multi-product blocks, usually at ₹25–500 crore turnover, and sell to formulators in India and abroad. A single reactor train makes many molecules in campaigns. The cost of any one product therefore depends on how well the plant ran during the weeks it was being made. Promoters and finance heads usually own the question, often with the plant head.

Who usually engages us

Promoter or managing director, often with the plant head and finance head

The economics

How the money moves in this trade

An API plant converts key starting materials and intermediates through several chemical steps. Each step has its own yield, solvent consumption and cycle time. Cost is driven less by the input price than by how much input survives each step, how much solvent is recovered, and how long the block sits idle for cleaning. A standard cost set at validation can drift a long way from what the plant achieves a few years later.

On the selling side, prices are negotiated molecule by molecule with formulators who compare suppliers across countries. A large share of sales is often exported on credit terms. Key starting materials are frequently imported, so one molecule can carry currency exposure on both its input and its output. The margin is squeezed between them.

The problem

Where the numbers usually break down

Standard yields are never refreshed

Cost sheets carry the yield recorded at process validation. When actual yields fall step by step, the shortfall is absorbed into overall material consumption and never reaches the product that caused it.

Solvent recovery is not valued

Recovered solvent re-enters the process without a cost, and losses in recovery are invisible. A molecule that consumes a large volume of fresh solvent looks no more expensive than one that recycles most of it.

Changeover and cleaning time is unallocated

Days spent cleaning a block between campaigns are treated as general overhead, so short campaigns of low-volume molecules appear cheaper to make than they are.

Starting-material exposure is not tracked by molecule

Imported key starting materials are bought in bulk and drawn across products, so a change in their price or availability cannot be traced to the molecules and customers it affects.

Rejected and reprocessed batches lose their cost

Batches that fail specification and are reworked or held under investigation sit in inventory at standard cost, with the reprocessing cost spread across the month's production.

What we do

The work, and the result each part produces

Campaign costing from the batch record

Actual material, solvent, utilities and block time booked against each campaign, step by step, and compared with the standard cost sheet.

Every campaign shows what the molecule really cost to make.

Yield variance by step

Actual against standard yield reported for each reaction step, valued at the cost of the material lost.

Yield loss becomes a number attached to a product and a step, not a general overrun.

Solvent balance and recovery costing

Fresh solvent, recovered solvent and losses reconciled by block, with recovery cost charged to the products that use it.

Solvent-heavy molecules carry their true cost.

Block-time and changeover allocation

Block hours, including cleaning and idle time between campaigns, charged to products on a stated basis.

Low-volume molecules are priced with their changeover cost included.

Molecule and customer contribution

Contribution by molecule and buyer after freight, currency movement, payment terms and rejected batches.

Price negotiations with formulators start from a known margin.

Export and input working capital

Export receivables, imported starting-material payables, inventory under quality hold and export-incentive balances tracked together.

The cash locked between purchase and realisation is visible each month.

Where we start

The first steps of an engagement

  1. Batch records and cost sheets

    We ask for the standard cost sheets, batch manufacturing record quantities by step, solvent recovery logs and block occupancy for recent campaigns. We also take the ERP stock and consumption ledgers they should agree with.

  2. Actual against standard, by campaign

    We rebuild the cost of recent campaigns from actual yield, fresh and recovered solvent and block hours. Each one is then set against the standard the ERP is still using.

  3. One campaign reference throughout

    Production logs are tied to the books with a single campaign reference. Yield by step and solvent issued, recovered and lost are then captured the same way every time.

  4. Campaign cost and contribution report

    The first report shows actual against standard cost for each campaign and yield loss valued by step. It also shows contribution by molecule and buyer, so the gaps large enough to change pricing stand out.

How it is measured

The reports the work is judged on

Each is recorded as a baseline before the work starts, so later reports have an honest comparison.

  • Actual against standard cost, by campaign
  • Yield variance by molecule and step
  • Solvent consumption and recovery by block
  • Block utilisation, including changeover time
  • Contribution by molecule and customer
  • Inventory under quality hold, by age and value

Who it suits

Written for, and not the right fit for

Not the right fit if
  • You need the plant's statutory, cost or tax audit report signed — those are signed by independently engaged licensed professionals.
  • You need help with drug master files, regulatory filings or an inspection response; those sit with your regulatory and quality teams.
Written for
  • API and intermediate manufacturers running multi-product blocks for domestic and export buyers.
  • Promoter-run plants whose cost sheets were last rebuilt at validation and no longer match the plant.
  • Manufacturers weighing a new block, a backward-integration project or a bank renewal.

Common questions

Questions owners in this trade ask

Our ERP already has a standard cost for every product. Why rebuild it?

The standard is only as good as the yields and cycle times behind it. Comparing it with actual campaigns usually shows a handful of molecules where the gap is large enough to change how you price them, and those are the ones worth fixing first.

Do you need access to the batch manufacturing record?

We need the quantities from it — inputs, outputs, solvent and time by step — not the full quality document. Most plants already capture these in production logs, so the work is in tying them to the books consistently.

Does our API plant need a cost audit?

It depends on turnover thresholds and on exemptions in the cost records and audit rules, so it's worth confirming each year with your cost auditor. Where one applies, we prepare the cost records and reconciliations the auditor relies on. The audit itself is performed and signed by an independently engaged cost accountant, which we can coordinate.

Scope and professional coordination

5th Quadrant performs costing, inventory accounting, control and reporting work. Drug licensing, regulatory filings and quality matters sit with your own regulatory and quality functions and the relevant authorities. Statutory audit, cost audit where it applies, and prescribed certification are performed by independently engaged licensed professionals, coordinated through 5th Quadrant. Full detail is on our Professional Scope page.

Explore further

Other trades in this sector

Back to Pharmaceutical and life sciences ↗

Tell us how your business actually runs.

Discuss your requirements